The average one-year price target for Landos Biopharma (NASDAQ:LABP) has been revised to 10.20 / share. This is an increase of 81.82% from the prior estimate of 5.61 dated June 1, 2023. The price ...
Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to ...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. By way of example, Landos Biopharma (NASDAQ:LABP) has seen its share ...
Investors are always looking for stocks that are poised to beat at earnings season and Landos Biopharma, Inc. LABP may be one such company. The firm has earnings coming up pretty soon, and events are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results